Lung Cancer News and Research RSS Feed - Lung Cancer News and Research Twitter

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
NSCLC treatments market in Europe expected to cross US$ 3 billion by 2019

NSCLC treatments market in Europe expected to cross US$ 3 billion by 2019

According to recently published Pharmaion report, "Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020", the non-small cell lung cancer (NSCLC) treatments market in Europe is anticipated to cross US$ 3 billion by 2019. [More]
New report reveals striking variation in cancer burden within AANHPI population

New report reveals striking variation in cancer burden within AANHPI population

A new report describes cancer among Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPIs), and reports striking variation in the cancer burden within this population, reflecting vast differences in exposure to cancer risk factors. [More]
Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

The cancer drug paclitaxel just got more effective. For the first time, researchers from the University of North Carolina at Chapel Hill have packaged it in containers derived from a patient's own immune system, protecting the drug from being destroyed by the body's own defenses and bringing the entire payload to the tumor. [More]
MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

In an international first, people with lung cancer will find out if a new combination of drugs can kick-start their bodies' ability to fight back against the disease. They'll be part of a clinical trial now enrolling participants at the Medical University of South Carolina. [More]
CPMC study discovers six genes that affect sleep duration

CPMC study discovers six genes that affect sleep duration

The Coriell Personalized Medicine Collaborative, a research initiative exploring the utility of genetic information in the clinical setting, has published a study and identified six noteworthy genes that affect human sleep duration. [More]
Malaysian scientists join forces with Harvard experts to help revolutionize lung disease treatment

Malaysian scientists join forces with Harvard experts to help revolutionize lung disease treatment

Malaysian scientists are joining forces with Harvard University experts to help revolutionize the treatment of lung diseases -- the delivery of nanomedicine deep into places otherwise impossible to reach. [More]
CTCA at Western announces launch of Phase II NivoPlus clinical trial

CTCA at Western announces launch of Phase II NivoPlus clinical trial

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has announced the launch of Phase II of the NivoPlus clinical trial, which combines the immunotherapeutic agent nivolumab with chemotherapy drugs irinotecan and capecitabine. [More]
Salk Institute scientists find new target for glioblastoma multiforme treatment

Salk Institute scientists find new target for glioblastoma multiforme treatment

Glioblastoma multiforme is a particularly deadly cancer. A person diagnosed with this type of brain tumor typically survives 15 months, if given the best care. The late Senator Ted Kennedy succumbed to this disease in just over a year. [More]
Auranofin drug could improve prognosis for ovarian cancer patients exhibiting BRCA1 deficiency

Auranofin drug could improve prognosis for ovarian cancer patients exhibiting BRCA1 deficiency

An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests. [More]
Screening smokers with community-acquired pneumonia could facilitate early diagnosis of lung cancer

Screening smokers with community-acquired pneumonia could facilitate early diagnosis of lung cancer

Lung cancer is the leading cause of cancer mortality in the United States, with a five-year survival rate of just 17 percent. Smoking causes approximately 85 percent of all lung cancer cases, only 15 percent of which are diagnosed at an early stage. Most efforts to obtain early diagnosis have been unsuccessful, largely due to the highly aggressive nature of the disease. [More]
Cancer mortality continues to drop in the U.S.

Cancer mortality continues to drop in the U.S.

Steady reductions in smoking combined with advances in cancer prevention, early detection, and treatment have resulted in a 23% drop in the cancer death rate since its peak in 1991. The drop translates to more than 1.7 million cancer deaths averted through 2012. [More]
Pancreatic cancer to surpass breast cancer to become third leading cause of deaths in U.S.

Pancreatic cancer to surpass breast cancer to become third leading cause of deaths in U.S.

Pancreatic cancer is expected to surpass breast cancer to become the third leading cause of cancer-related deaths in the United States, according to the latest Cancer Statistics 2016 report, published today by the American Cancer Society in CA: A Cancer Journal for Clinicians. [More]
Biocept introduces blood-based test for detection, monitoring of prostate cancer and breast cancer

Biocept introduces blood-based test for detection, monitoring of prostate cancer and breast cancer

Biocept, Inc., a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient's blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer. [More]
Statins could be effective against metastatic small cell lung cancer

Statins could be effective against metastatic small cell lung cancer

In a recent study, researchers at Cancer Treatment Centers of America at Western Regional Medical Center (Western), in collaboration with international colleagues, found that statins could be an effective therapeutic against metastatic small cell lung cancer (SCLC). [More]
NIH-funded clinical study examines new method for sparing healthy lung tissue during radiotherapy

NIH-funded clinical study examines new method for sparing healthy lung tissue during radiotherapy

A newly NIH funded clinical trial (NCT02528942) by University of Colorado Cancer Center investigators and collaborators at Beaumont Health in Michigan and the University of Texas Medical Branch is evaluating a new method for pinpointing and sparing healthy lung tissue during lung cancer radiotherapy. [More]
Pediatric oncologists devise new treatments for neuroblastoma

Pediatric oncologists devise new treatments for neuroblastoma

Pediatric oncologists from The Children's Hospital of Philadelphia have reported their latest results in devising new treatments for stubbornly deadly forms of the childhood cancer neuroblastoma. [More]
SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC). [More]
Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

Xcovery, a developer of targeted therapeutics for ALK+ non-small cell lung cancer (NSCLC) is scheduled to present January 6th, 2016 at the fourth annual AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, at the Hard Rock Hotel, in San Diego, CA. [More]
NCCLC patients with KRAS-related gene mutations may benefit from triple therapy

NCCLC patients with KRAS-related gene mutations may benefit from triple therapy

Although the most common type of lung cancer - non-small cell lung cancer (NSCLC) - has recently seen major treatment advances in some genetic subtypes, other subtypes continue to evade effective treatment. (New therapies exist for NCCLC patients whose cancers harbor mutations in the ALK or EGFR genes, for example.) [More]
FDA approves non-alcoholic Docetaxel Injection

FDA approves non-alcoholic Docetaxel Injection

Teikoku Pharma USA, Inc. announced today that the U.S. Food and Drug Administration has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel Injection") for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. [More]
Advertisement